Submodule
Lipoprotein Architecture and Transport
Intestinal apoB-48 chylomicrons and hepatic apoB-100 VLDL transport hydrophobic lipid through plasma, undergo lipolysis and remodeling, and return through remnant or LDL receptor pathways.
- Particle architecture
- Chylomicron pathway
- VLDL to LDL remodeling
- LDL receptor clearance
Deliver dietary triglyceride
Export endogenous triglyceride
Lipolysis changes cargo, not particle ancestry
Particle residence shapes arterial exposure
Build the particle
A hydrophobic core of triglyceride and cholesteryl ester is surrounded by phospholipid, free cholesterol, and apolipoproteins. The surface makes transport possible, while apolipoproteins organize structure, enzymes, receptors, and particle identity.
Trace dietary lipid
Enterocytes package dietary triglyceride with apoB-48 into chylomicrons. Lipoprotein lipase releases fatty acids to tissues, and the cholesterol-enriched remnant returns to the liver. ApoC-II supports LPL, while apoC-III can inhibit clearance.
Trace hepatic lipid
The liver secretes apoB-100 VLDL. Lipolysis removes triglyceride as VLDL becomes remnant, IDL, and sometimes LDL. One apoB-100 remains with a particle through this sequence, so remodeling changes cargo without creating a new particle at every step.
Clear LDL through its receptor
LDL receptor recognition of apoB-100 limits particle residence. Defects in LDLR, apoB binding, receptor recycling, or clearance can produce severe lifelong exposure. Secondary causes must still be excluded before assigning an inherited phenotype.
Quick check
Submodule
LDL-C, Non-HDL-C, ApoB, and Cumulative Burden
LDL-C measures cholesterol cargo, non-HDL-C includes cholesterol across atherogenic fractions, and apoB approximates particle number. Discordance reveals why one marker may not tell the whole story.
- Cholesterol mass
- Atherogenic particle number
- Marker discordance
- Concentration across time
Primary screening and treatment metric
Captures LDL plus remnant cholesterol
Clarifies discordance in selected patients
Cumulative exposure drives disease
Interpret LDL-C correctly
LDL-C estimates cholesterol mass in LDL particles. It remains the central screening and treatment metric, but it is not a direct particle count. Cholesterol per particle varies with triglyceride metabolism and treatment.
Use non-HDL-C to widen the lens
Non-HDL-C is total cholesterol minus HDL-C. It includes LDL cholesterol plus cholesterol in VLDL, IDL, remnants, and Lp(a), making it useful when triglyceride-rich apoB particles contribute.
Use apoB selectively
Each major atherogenic particle contains one apoB molecule. ApoB can clarify burden in diabetes, metabolic syndrome, high triglycerides, treated ASCVD, or other discordant states where LDL-C may underestimate particle count.
Think in particle-years
Atherosclerosis reflects both concentration and duration. Severe LDL elevation beginning in childhood can produce high lifetime burden even when a young person's ten-year risk is low.
Quick check
Submodule
Triglyceride-Rich Remnants and Pancreatitis Risk
Triglyceride elevation can signal insulin-resistant VLDL overproduction, impaired lipolysis, remnant particle burden, or severe chylomicronemia with acute pancreatitis risk.
- Production and clearance
- Remnant ASCVD biology
- Severe hypertriglyceridemia
- Familial chylomicronemia
Diet, liver, insulin, and genetics shape output
ApoC-II activates while apoC-III inhibits
Particle cholesterol can enter the arterial wall
Acute pancreatitis prevention becomes urgent
Balance production and clearance
The liver exports VLDL in response to fatty acid supply, insulin resistance, and energy excess. LPL-mediated lipolysis and remnant uptake clear triglyceride-rich particles. Genetics, diabetes, alcohol, pregnancy, kidney disease, and medicines can shift either side.
Recognize remnant risk
Partially lipolyzed remnants contain apoB and cholesterol and can enter the arterial wall. Triglycerides are therefore a marker of a broader atherogenic particle environment, not simply a neutral storage molecule.
Protect the pancreas at severe levels
Marked chylomicron accumulation changes the immediate goal. Assess abdominal symptoms and rapidly address alcohol, uncontrolled diabetes, medications, diet, pregnancy, thyroid, kidney, and other drivers while using specialist-directed dietary and pharmacologic care.
Separate FCS from multifactorial disease
Familial chylomicronemia syndrome is rare and usually presents with early persistent severe triglycerides and pancreatitis from biallelic LPL-pathway dysfunction. Multifactorial chylomicronemia is more common and reflects genetic susceptibility plus secondary stressors.
Quick check
Submodule
Inherited and Secondary Dyslipidemia
Level, pattern, age, family history, examination, physiology, medicines, and response distinguish familial hypercholesterolemia, Lp(a), chylomicronemia, mixed genetic risk, and acquired causes.
- Familial hypercholesterolemia
- Lipoprotein(a)
- Secondary causes
- Cascade assessment
Age and family history raise probability
Treat the driver and the lipid risk
Physiology changes both values and treatment
Timing can reveal a reversible cause
Recognize familial hypercholesterolemia
Marked untreated LDL-C, premature ASCVD, tendon xanthomas, and affected relatives raise FH probability. LDLR, APOB, and PCSK9 are major pathways, but a negative panel does not exclude a clinical or polygenic phenotype.
Measure Lp(a) at least once
Lp(a) is an LDL-like apoB-100 particle linked to apo(a), and its level is largely genetic. The 2026 guideline recommends at least one adult measurement. Reported mass and molar units should not be converted with one universal factor.
Find secondary causes
Diabetes, hypothyroidism, nephrotic or chronic kidney disease, liver disease, pregnancy, alcohol, nutrition, weight change, and medications can create or amplify dyslipidemia. Correct the driver while treating residual risk when needed.
Use family cascade assessment
A severe inherited phenotype is information for relatives. Cascade lipid testing, and genetics when useful, can detect risk before symptoms. Family history must include age and type of vascular event rather than only the word heart disease.
Quick check
Submodule
Screening, Sampling, and Measurement Limits
The 2026 framework starts adult screening at 19, adds universal childhood screening at 9 to 11, and uses fasting status, laboratory equation, and advanced markers according to the clinical question.
- Adult and childhood screening
- Fasting versus nonfasting
- Calculated LDL limits
- Repeat measurement
Earlier with FH or premature ASCVD family history
Repeat generally every five years when low risk
Risk context changes timing and decisions
Repeat after treatment or major clinical change
Screen across the life course
Adults begin universal lipid screening at 19, generally every five years when low risk and untreated. Children are universally screened at 9 to 11, with earlier testing when familial hypercholesterolemia or premature family ASCVD is suspected.
Use nonfasting panels appropriately
Nonfasting lipids are suitable for many routine assessments. Fasting measurement is useful when severe triglycerides, pancreatitis risk, inherited phenotyping, or an equation limitation requires clarification.
Know how LDL-C was obtained
Calculated LDL-C depends on relationships among total cholesterol, HDL-C, and triglycerides. Equation error grows in selected high-triglyceride or very-low-LDL states. Non-HDL-C, apoB, direct measurement, or a validated alternate equation may answer the question better.
Repeat when biology changes
Repeat after treatment initiation or adjustment, major weight or glycemic change, pregnancy transition, acute illness resolution, correction of a secondary cause, or an unexpected value. A low-risk untreated interval does not apply to active management.
Quick check
Submodule
PREVENT Risk, Enhancers, and Coronary Calcium
The 2026 guideline uses PREVENT-ASCVD, new risk categories, personalized enhancers, and selective coronary calcium to convert population evidence into a shared primary-prevention decision.
- PREVENT 10- and 30-year risk
- Borderline, intermediate, and high categories
- Risk enhancers
- CAC reclassification
Use current primary-prevention equations
Add information outside the calculator
Use when the medication decision remains uncertain
Match lifelong burden and current absolute risk
Use the current calculator
PREVENT-ASCVD replaces the pooled cohort equations for primary-prevention lipid decisions. Use verified inputs and examine both 10- and 30-year risk when applicable, especially when age makes short-term risk look deceptively low.
Use the new categories
Borderline ten-year risk is 3 to below 5 percent, intermediate is 5 to below 10 percent, and high begins at 10 percent. The category frames treatment intensity and goals but does not replace LDL severity, special populations, or preference.
Personalize with enhancers
Premature family ASCVD, inflammatory disease, reproductive risk markers, biomarkers, CKD, HIV, triglycerides, Lp(a), apoB when useful, and other factors can add information outside the calculator. Avoid counting the same factor twice.
Use CAC when uncertainty remains
Coronary artery calcium can reclassify selected adults when a primary-prevention medication decision remains uncertain. It is not a test for acute symptoms and does not exclude noncalcified plaque. Each possible result should have a planned consequence before imaging.
Quick check
Submodule
Established ASCVD and Special-Population Risk
Established ASCVD, diabetes, stage 3 or worse CKD, HIV, pregnancy and reproductive history, young severe LDL, childhood disease, and older age require pathways beyond one generic score.
- Secondary prevention
- CKD and HIV
- Diabetes and CKM risk
- Pregnancy, youth, and older adults
Earlier with FH or premature ASCVD family history
Repeat generally every five years when low risk
Risk context changes timing and decisions
Repeat after treatment or major clinical change
Do not calculate away established disease
Clinical ASCVD establishes recurrent-event risk and bypasses primary-prevention calculation. Determine very-high-risk features, untreated and current lipids, adherence, tolerance, and the LDL-C and non-HDL-C goals that match the 2026 pathway.
Recognize CKD and HIV pathways
Adults 40 to 75 with stage 3 or worse CKD or HIV generally have guideline-supported primary-prevention lipid therapy independent of LDL-C or PREVENT score. Organ function and antiretroviral interactions still determine the product plan.
Integrate diabetes and CKM risk
Diabetes duration, age, kidney disease, albuminuria, hypertension, smoking, and other complications change intensity. ApoB can clarify residual particle burden when insulin resistance and triglycerides create LDL-C discordance.
Use a lifecourse and reproductive lens
Young adults with LDL-C at least 160 or strong premature family history may merit earlier therapy. Pregnancy and lactation require product-specific planning rather than legacy letter categories. Older adults require benefit, frailty, interactions, cognition, goals, and lifespan assessment.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.